HEPARINASE HR ACT CONTROL, MODEL 550-12

K042175 · Medtronic Vascular · GGN · Oct 18, 2004 · Hematology

Device Facts

Record IDK042175
Device NameHEPARINASE HR ACT CONTROL, MODEL 550-12
ApplicantMedtronic Vascular
Product CodeGGN · Hematology
Decision DateOct 18, 2004
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 864.5425
Device ClassClass 2

Intended Use

To verify the performance of the ACT instrument and the Heparinase (HR HTC) cartridges

Device Story

CLOTtrac® HTC Control is an in vitro diagnostic device used to verify performance of ACT (Automated Coagulation Timer) instruments and Heparinase (HR HTC) cartridges. Device functions as a quality control material; ensures accuracy of coagulation testing. Used in clinical settings by healthcare professionals. Output provides verification of instrument and cartridge functionality; assists in maintaining quality assurance for coagulation monitoring.

Clinical Evidence

Bench testing only; validation testing performed to establish performance characteristics of modifications relative to the predicate device.

Technological Characteristics

Lyophilized control material; composition: citrated sheep plasma, stabilized sheep erythrocytes, USP porcine heparin. Reconstituted to 6 U/mL. Designed for use with ACT instrumentation and HR-HTC cartridges. Stability: 2 hours at 15°-25° C post-reconstitution. Storage: 2°-10° C. Risk management per ISO 14971.

Indications for Use

Indicated for verifying the performance of the ACT instrument and Heparinase (HR HTC) cartridges.

Regulatory Classification

Identification

A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.

Special Controls

*Classification.* Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K042175 # OCT 1 8 2004 ## 510(k) Summary | Date Prepared: | September 28, 2004 | |---------------------------------|--------------------------------------------------------------------------------------------------------------| | Submitter: | Medtronic Perfusion Systems<br>7611 Northland Boulevard<br>Brooklyn Park, MN 55428 | | Contact Person: | Dawn M. Stenstrom<br>Principal Regulatory Affairs Specialist<br>Phone: (763) 391-9604<br>Fax: (763) 391-9603 | | Device Name and Classification: | | | Trade Name: | CLOTtrac® HTC Control | | Common Name: | Activated Whole Blood Clotting Time | | Classification: | Class II | | Predicate Devices: | Heparinase HR ACT Control<br>K902081 | #### Device Description: The CLOTtrac® HTC Control is an in vitro diagnostic device. This control is intended to TIC CEO Fudos TF C Collier CT instrument and the Heparinase (HR HTC) cartridges. The cartridge is for use in the ACT (Automated Coagulation Timer) instrument. ### Indication for Use This product is intended to verify the performance of the ACT instrument and the Heparinase (HR HTC) cartridges #### Comparison to Predicate Device The predicate device, Heparinase HR ACT control is currently marketed. The THE Preac® HTC Control has the same indications for use and is the same in all aspects to the modified control with exception of the source of heparin. #### Summary of Performance Data Validation testing was used to establish the performance characteristic of the modifications of this device from the previously marketed device. ## Conclusion Medtronic has demonstrated that the CLOTtrac® HTC Control is substantially equivalent to the predicate device based upon design, test results, and indications for use. {1}------------------------------------------------ Image /page/1/Picture/0 description: The image shows the seal of the Department of Health & Human Services - USA. The seal features an eagle with three lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Ms. Dawn M. Stenstrom Principal Regulatory Affairs Specialist Medtronic Perfusion Systems 7611 Northland Drive N Minneapolis, MN 55428-1088 OCT 1 8 2004 k042175 Re: Trade/Device Name: CLOTtrac® HTC Control Regulation Number: 21 CFR § 864.5425 Regulation Name: Multipurpose system for in vitro coagulation studies Regulatory Class: II Product Code: GGN, JBP Dated: September 28, 2004 Received: September 29, 2004 Dear Ms. Stenstrom: We have reviewed your Section 510(k) premarket notification of intent to market the device wt have reviewed your because a sees per is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use stated in the encrosale) to togens and ment date of the Medical Device Amendments, or to commerce pror to May 20, 1978, the excordance with the provisions of the Federal Food, Drug, devices that have been recensement asse approval of a premarket approval application (PMA). and Cosmetor For (10) that do never, subject to the general controls provisions of the Act. The r ou may, merelore, manel and act include requirements for annual registration, listing of general controls provisions practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your device is classified (600 a0070) ins. Existing major regulations affecting your device can may be subject to such additional controls. Existing major regulations aff may be subject to suel additions (CFR), Parts 800 to 895. In addition, FDA be found in Thre 21, Ocouncements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean I loase be activised that I Drivision that your device complies with other requirements of the Act that I Dr Has made a aond regulations administered by other Federal agencies. You must of any I cacal statutes and regairements, including, but not limited to: registration and listing (21 compry with an the Free 22 CFR Parts 801 and 809); and good manufacturing practice CITY art 607), laooning (21 OF Ready systems (QS) regulation (21 CFR Part 820). This letter requirements as set form in the quartly advice as described in your Section 510(k) premarket whil anow you to begin marketing your intial equivalence of your device to a legally marketed nunfication. THE I Driving of the intention for your device and thus, permits your device to proceed to the market. {2}------------------------------------------------ Page 2 If you desire specific information about the application of labeling requirements to your device, If you desire specific information about the appears device, please contact the Office of In or questions on the promotion and advertising of your device, please contact the of questions on the promotion and acrestions 2019 594-3084. Also, please note the Vitto Diagnostic Device Lyanaaton and Baroy at (3 co verset on the moder the Ast from the fegulation entitled, "Misoranting of responsibilities under the Act from the take the tall from the You may of all other general informational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours, Robert L. Becker Jr. Robert L. Becker, Jr., M.D., Ph/ Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ Indications for Use 510(k) Number (if known): K042175 Device Name: ## CLOTtrac® HTC Control Indications for Use: To verify the performance of the ACT instrument and the Heparinase (HR HTC) cartridges Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ AND/OR Prescription Use _____________________________________________________________________________________________________________________________________________________________ (21 CFR 807 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Josephine Brutaka Division Sigh-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K042175 Page _1_ of _1__
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...